Why the study?
Does chronic cholesterol-reducing therapy improve skeletal muscle arteriolar reactivity, microvessel density, inflammation, and NO bioavailability in male obese Zucker rats?
Does chronic cholesterol-reducing therapy improve skeletal muscle arteriolar reactivity, microvessel density, inflammation, and NO bioavailability in male obese Zucker rats?
In the obese Zucker rat model of metabolic syndrome, chronic statin treatment improves vascular NO bioavailability, attenuates microvessel rarefaction, and reduces inflammation independently of total cholesterol reduction.
No takes yet. Share an insight, caveat, or question.
Statin-specific microvascular protection beyond cholesterol lowering in metabolic syndrome models; hypothesis-generating and should not yet change practice.
Goodwill et al. (2009) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: